Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients

• Published in: Journal of international medical research 2023-11, Vol.51 (11), p.3000605231212316-3000605231212316
• Main Authors: Noiphithak, Raywat, Duangprasert, Gahn, Sukhor, Sasikan, Durongkaweroj, Pichayaphong, Yindeedej, Vich
• Format: Article
• Language: English
• Subjects: Blood pressure; Cardiac arrhythmia; Hypotension
• ISSN: 0300-0605; 1473-2300
• DOI: 10.1177/03000605231212316

Objectives Current evidence supporting the use of continuous intravenous labetalol for blood pressure (BP) control in neurosurgical patients is limited. This study aims to assess the efficacy and safety of labetalol in neurosurgical patients and identify potential contributing factors to these outcomes. Methods We retrospectively reviewed the medical records of neurosurgical patients who received continuous labetalol infusion for BP control. Efficacy was assessed based on the time needed to achieve the target BP (systolic BP ≤ 140 mmHg or diastolic BP ≤ 90 mmHg). Safety was assessed according to adverse events that occurred during labetalol administration. Factors associated with efficacy and safety were analyzed using a logistic regression model. Results Among 79 patients enrolled in this study, 47 (59.49%) achieved the target BP within 1 hour (early response). No factors were significantly associated with an early response. Hypotension was observed in 11 patients (13.9%), and bradycardia was observed in 8 patients (10.1%). Hypotension was significantly associated with patient age and motor impairment, while bradycardia was significantly associated with diabetes mellitus. Conclusion The efficacy and safety profiles of labetalol infusion suggest this treatment as a promising option for BP control in neurosurgical patients.